Rancho Cordova, CA, March 20, 2015 -- SureClinical Inc., an industry-leader in collaborative cloud health sciences applications, announced today a strategic partnership with Triumph Consultancy Services to broaden its eTMF service delivery portfolio. With offices in London, UK, and Raleigh, USA, Triumph is well positioned to provide SureClinical’s growing global customer base with specialized implementation and validation services.
Triumph has been operating for 13 years and has gained significant experience with both Pharma and CRO companies, across small, medium and large organizations. Triumph uses its wealth of clinical knowledge and experience to ensure each project is optimized to the needs of the customer and is delivered efficiently and effectively. Triumph provides both strategic and operational services around technology selection, process reengineering, organizational change management, training delivery, regulatory compliance management, and key performance metric (KPIs) study analysis.
“We are thrilled to partner with Triumph. Their consultative approach to service engagements, ensuring the needs of the customer are put first, as well as their solid track record in clinical system implementation is impressive. Clients can be assured of the very best guidance in both implementing SureClinical eTMF as well as integrating the solution with existing clinical systems.” said Chris Ibell, Chief Strategy Officer and President SureClinical Europe. “Like Triumph, SureClinical is committed to providing a best-in-class cloud eTMF that is immediately accessible to sponsors and their CROs, thereby improving study ROI. Triumph delivers a range of modularized, portfolio services that will ensure a successful implementation of SureClinical eTMF, deployed on a global, FDA and EC-compliant Certified Cloud™."
“We are excited to include the SureClinical Cloud eTMF within our technology services portfolio,” said Duncan Hall, CEO of Triumph. "SureClinical is on the forefront of delivering electronic Trial Master File capture, completion, and digital signing with the latest cloud and mobile technologies. With the majority of clinical regulatory documents still captured on paper, we see a great opportunity to provide SureClinical customers with Triumph’s best practice processes and training accelerators when transitioning their Trial Master File processes to the cloud."
SureClinical eTMF Cloud – Shred the Paper Mountain (TM)
SureClinical’s SureWorkflow and patent-pending high trust digital signing is part of an integrated solution, enabling clinical trial sponsors, CRO’s, investigators and stakeholders to collaborate, complete and Esign documents through automated workflows, eliminating paper at its origin. CRO’s, sponsors, and investigators can readily and securely sign documents from any connected mobile device, anywhere in the world without opening ports in firewalls or requiring federation of security. Moreover, since it is Cloud, SureClinical customers can activate studies within minutes delivering scale-up and scale-down flexibility based on need, without having to invest in underused on premise infrastructure or software. SureClinical eTMF Cloud automates and streamlines clinical processes, eliminates paper, which is good for the customer, environment, industry, and the customer’s bottom-line.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.